Allay Pharmaceuticals, LLC

Form 483 issued November 15, 2021 · Miami, Florida

Inspection
Oct 25 – Nov 15, 2021
Observations
2
Pages
4
FEI number
3007007565

In short: On November 15, 2021, FDA issued a Form 483 with 2 observations to Allay Pharmaceuticals, LLC in Miami, Florida (FEI 3007007565) after an inspection that ran Oct 25 – Nov 15, 2021. The investigators were Clinton J. Lott and Joanne E. King. Most observations concern quality system and production; the most-cited regulation is 21 CFR 211.186 (master production and control records).

At a glance

Quality system and production account for 2 of 2 observations.

Quality system1
Production1

Most cited: 21 CFR 820 (1×) · 211.186(b)(9) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01
    21 CFR 820

    The responsibilities and procedures applicable to the quality control unit are not in…

  2. 02

    Master production and control records lack complete manufacturing and control instructions and…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Allay Pharmaceuticals, LLC?

FDA listed 2 observations on this Form 483, mostly about quality system and production. The most-cited regulation is 21 CFR 211.186 (master production and control records). The opening words of each observation are shown on this page.

Who inspected Allay Pharmaceuticals, LLC?

Clinton J. Lott and Joanne E. King are named on this Form 483, for the inspection of Oct 25 – Nov 15, 2021. Each investigator has a profile showing what they cite most.

When was Allay Pharmaceuticals, LLC inspected by FDA?

The inspection ran Oct 25 – Nov 15, 2021, and the Form 483 is dated November 15, 2021.

How do I get the full Form 483 for Allay Pharmaceuticals, LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free